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Despite intensive antihypertensive therapy there was a high
incidence of renal end points in participants of the African
American Study of Kidney Disease and Hypertension (AASK)
cohort. To better understand this, coding variants in the
apolipoprotein L1 (APOL1) and the nonmuscle myosin heavy
chain 9 (MYH9) genes were evaluated for an association with
hypertension-attributed nephropathy and clinical outcomes
in a case–control study. Clinical data and DNA were available
for 675 AASK participant cases and 618 African American
non-nephropathy control individuals. APOL1 G1 and G2,
and MYH9 E1 variants along with 44 ancestry informative
markers, were genotyped with allele frequency differences
between cases and controls analyzed by logistic regression
multivariable models adjusting for ancestry, age, and gender.
In recessive models, APOL1 risk variants were significantly
associated with kidney disease in all cases compared to
controls with an odds ratio of 2.57. In AASK cases with
more advanced disease, such as a baseline urine protein
to creatinine ratio over 0.6 g/g or a serum creatinine over
3mg/dl during follow-up, the association was strengthened
with odds ratios of 6.29 and 4.61, respectively. APOL1 risk
variants were consistently associated with renal disease
progression across medication classes and blood pressure
targets. Thus, kidney disease in AASK participants was
strongly associated with APOL1 renal risk variants.
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African Americans are more likely to develop progressive kidney
disease compared with European Americans,1 and this risk
extends across the leading causes of end-stage kidney disease
(ESKD): diabetes, hypertension-attributed kidney disease, and
glomerulonephritis.2 In particular, for hypertension-attributed
nephropathy, there is a threefold increase in incidence of ESKD
for African Americans overall, which is magnified at younger ages.
The genetic contribution to the increased prevalence of
hypertension-attributed ESKD is now better understood.
In the past several years, a region on chromosome (chr) 22
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associated with renal disease in African Americans was
identified using mapping by admixture disequilibrium. This
region contains the nonmuscle myosin heavy chain 9 (MYH9)
and apolipoprotein L1 (APOL1) genes. Initial studies that
detected the association in this region showed a very strong
association of MYH9 with human immunodeficiency virus–
associated nephropathy and focal segmental glomerulo-
sclerosis (FSGS),3,4 as well as an association with nondiabetic
forms of ESKD.3,5
More recent studies have shown that there is an even
stronger association of the APOL1 gene with FSGS and
hypertension-attributed ESKD than with MYH9 among
African Americans. Controlling for APOL1 risk alleles showed
no residual effect of the MYH9 gene, whereas controlling for
MYH9 genotype did not significantly weaken the effect of
APOL1.6,7 Although these data suggested little role for the
MYH9 risk alleles, it has subsequently been shown that
MYH9 risk alleles are associated with increased risk of
nondiabetic chronic kidney disease (CKD) and diabetic
ESKD in individuals of European ancestry.8,9 In these studies,
there was no risk attributable to APOL1 genotypes; however,
the frequency of the APOL1 risk alleles was extremely low
among European Americans.
To further understand the role of APOL1 and MYH9
genetic variants in hypertension-attributed CKD, we have
performed a case–control study and evaluated the rate of
decline of measured iothalamate glomerular filtration rate
(GFR). African American cases were patients with CKD from
the African American Study of Kidney Disease and Hyperten-
sion (AASK) who at baseline had subnephrotic protein-
uria or no proteinuria, measured iothalamate GFR of
o65ml/min per 1.73m2, and clinically diagnosed hyperten-
sive nephropathy.10,11 Cases were compared with African
American controls with normal kidney function as
determined by history and serum creatinine measurement,
some with mild or moderate hypertension.
RESULTS
The characteristics of the African American cases and African
American control subjects are presented in Table 1. All of the
cases had hypertension and CKD. Of the controls, 410 were
questioned about the presence of hypertension, and of these
41.7% (171) reportedly were hypertensive based on physician
report or the use of antihypertensive medications. Those with
CKD were predominantly male and older compared with
controls and had similar body mass index and population
admixture. Cases had a low baseline GFR and elevated serum
creatinine, whereas controls had a mean serum creatinine
concentration of 1.0mg/dl.
All reported APOL1 and MYH9 SNPs were in Hardy–
Weinberg equilibrium (HWE) in the AASK participants
and in the controls. Although analyses were performed
Table 1 | Demographic and clinical information (% or mean (median) ±s.d.)
Cases
N=675
Controls
N=618 P-value
Sex (% female) 40% 57% o0.0001
Age (years) 54.1 (55)±10.6 49.1 (48)±11.7 o0.0001
BMI (kg/m2) 31.0 (30)±6.6 30.1 (29)±7.1 0.0103
Serum creatinine (mg/dl) 1.99 (1.8)±0.7 1.00 (0.9)±0.26 o0.0001
Mean baseline GFR (ml/min per 1.73m2) 47.2 (49)±13.4 NA —
Hypertension (% yes) 100% 41.7% of patients who were surveyed o0.0001
YRI admixture (%) 0.89 (0.93)±0.11 0.89 (0.92)±0.10 0.34
Abbreviations: BMI, body mass index; GFR, glomerular filtration rate; NA, not available; YRI, Yoruban.
African American cases were from the AASK (African American Study of Kidney Disease and Hypertension) study; 618 African American controls were recruited at Wake Forest
School of Medicine, and 171 of 410 evaluated reported hypertension.
Table 2 | Chromosome 22 genotype results
Gene SNP C22 position Risk allele
Risk allele
fraction, cases
Risk allele
fraction, controls
P-value,
recessive model
OR, recessive
model 95% CI
APOL1 rs16996616 36661891 A 0.09 0.07 3.18E-01 2.1 (0.49, 9.04)
APOL1G1 rs73885319 36661906 G 0.28 0.21 2.97E-06 3.47 (2.06, 5.85)
APOL1G1 rs60910145 36662034 G 0.28 0.20 2.77E-06 3.54 (2.09, 6.00)
APOL1G2 rs71785313 36662051 C 0.16 0.13 1.46E-01 1.72 (0.83, 3.57)
APOL1G1G2 0.44 0.34 1.39E-08 2.57 (1.85, 3.55)
MYH9 rs11912763 36684722 A 0.24 0.19 1.36E-03 2.56 (1.44, 4.54)
MYH9 E1 rs2032487 36695428 C 0.69 0.61 2.11E-04 1.56 (1.23, 1.97)
MYH9 E1 rs4821481 36695942 C 0.70 0.60 3.41E-05 1.65 (1.30, 2.09)
MYH9 rs5750250 36708483 A 0.42 0.50 1.07E-03 0.62 (0.47, 0.83)
MYH9 EI rs3752462 36710183 T 0.76 0.73 1.81E-02 1.33 (1.05, 1.68)
Abbreviations: OR, odds ratio; SNP, single nucleotide polymorphism.
Genotype results are shown for chromosome 22 alleles, including those in APOL1, those comprising the G1 and G2 alleles, and in MYH9 (including those SNPs comprising the
E1 haplotype). Data were adjusted for age, sex, and population admixture. Admixture outliers were excluded from analysis, leaving 675 cases and 618 controls.
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for the additive, dominant, and recessive models, the largest
effect sizes (odds ratios (ORs)) were observed for the
recessive model. This is consistent with the results of other
studies.6,7 The tables show the results for only the recessive
model; associations for the additive and dominant models
are presented in Supplementary Table S1 online, and APOL1
genotype frequencies are presented in Supplementary
Table S2 online. The results of the primary single-SNP
analysis are shown in Table 2. The associations of APOL1
G1 SNPs with CKD were highly significant and associated
with approximately a 3.5-fold risk for CKD for G1. The
G2 SNP was not significant, but, as in other studies6,7 was
present at lower allele frequencies than the other SNPs.
It should be noted that the more frequent G1 allele tends to
mask the effect of G2, as the two variants occur on opposing
chromosomes.
MYH9 SNPs showed significant associations with CKD,
but weaker than the APOL1 G1 and combined G1–G2
association. Analyses were repeated controlling for either the
combined APOL1 G1–G2 risk alleles or the MYH9 E1 SNP
rs4821481 using the recessive model, and the data are shown
in Table 3. Controlling for the APOL1 risk alleles attenuated
the effect of MYH9 SNPs: the E1-tagging SNP rs4821481
remained of borderline statistical significance. Controlling
for rs4821481 did not markedly decrease the effect of the
APOL1 G1 alleles.
Association results for the combined risk of APOL1 G1-G2
alleles on CKD are presented in Table 4 and the MYH9 E1
haplotype in Table 5. The statistical significance and OR
increased when comparing patients with more advanced
renal disease as measured by serum creatinine concentration
and proteinuria. This was particularly significant for the
APOL1 risk alleles, but was also apparent for the MYH9 E1
risk haplotype. The sensitivity analysis comparing subsets of
controls phenotyped for hypertension and normal blood
pressure (BP) shows ORs similar to that of the controls as a
Table 3 | Case vs. control comparisons, adjusted for MYH9
SNP rs4821481 or APOL1 combined risk alleles
Adjusted for MYH9
SNP rs4821481 APOL1 SNP
P-value,
cases/
controls
Odds
ratio 95% CI
rs16996616 2.44E-01 2.49 (0.54, 11.55)
rs73885319 (G1) 1.87E-04 2.78 (1.62, 4.76)
rs60910145 (G1) 1.69E-04 2.83 (1.65, 4.88)
rs71785313 (G2) 2.85E-01 1.50 (0.72, 3.14)
Adjusted for APOL1
combined risk alleles
MYH9 SNP
rs11912763 4.08E-01 1.32 (0.69, 2.52)
rs2032487 (E1) 1.20E-01 1.23 (0.95, 1.59)
rs4821481 (E1) 4.67E-02 1.30 (1.00, 1.69)
rs5750250 6.92E-02 0.76 (0.56, 1.02)
rs3752462 (E1) 6.73E-01 1.06 (0.82, 1.36)
Abbreviations: CI, confidence interval; SNP, single nucleotide polymorphism.
The top half of the table shows the effect of APOL1 SNPs, adjusted for the MYH9 SNP
rs48212481 using a recessive model. The bottom half of the table shows the effect
of MYH9 SNPs, adjusted for APOL1 combined risk alleles. Data were adjusted for age,
sex, body mass index, and population admixture.
Table 4 | Logistic regression model of the effect of APOL1 risk alleles on clinical phenotype
Outcome N (cases) N (controls) P-value OR, recessive model 95% CI
All AASK cases vs. controls 663 579 1.39E-08 2.57 (1.85, 3.55)
Cases with serum creatinine 42mg/dl or ESKD vs. controls 330 579 1.99E-12 3.64 (2.54, 5.21)
Cases with serum creatinine 43mg/dl or ESKD vs. controls 216 579 5.60E-15 4.61 (3.14, 6.76)
Cases with urine PCR o0.22 g/g vs. controls 457 579 0.0219 1.55 (1.07, 2.26)
Cases with urine PCR 40.22 g/g vs. controls 204 579 2.70E-15 4.85 (3.28, 7.18)
Cases with urine PCR 40.60 g/g vs. controls 105 579 2.62E-14 6.29 (3.92, 10.11)
Hypertensive kidney disease vs. hypertensive controls 663 158 0.0013 2.40 (1.41, 4.08)
Hypertensive kidney disease vs. non-hypertensive controls 663 220 8.52E-07 3.62 (2.17, 6.05)
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; CI, confidence interval; ESKD, end-stage kidney disease; OR, odds ratio; PCR, protein/
creatinine ratio.
Analysis using APOL1 risk alleles (G1 and G2) was adjusted for age, sex, and admixture.
Table 5 | Logistic regression analysis for the effect of the MYH9 E1 haplotype on clinical outcomes
Outcome N (cases) N (controls) P-value OR, recessive model 95% CI
Case–control 622 592 0.0002 1.60 (1.25, 2.05)
Serum creatinine 42mg/dl or ESKD 311 592 5.99E-06 1.99 (1.48, 2.68)
Serum creatinine 43mg/dl or ESKD 201 592 1.05E-08 2.68 (1.91, 3.76)
Urine PCR o0.22 g/g 431 592 0.0461 1.33 (1.01, 1.76)
Urine PCR 40.22 g/g 189 592 1.26E-05 2.38 (1.68, 3.36)
Hypertensive controls 622 167 0.0619 1.42 (0.98, 2.06)
Non-hypertensive controls 622 227 0.0019 1.74 (1.23, 2.47)
Abbreviations: CI, confidence interval; ESKD, end-stage kidney disease; OR, odds ratio; PCR, protein/creatinine ratio.
Shown are the results of logistic regression analysis using a recessive model for the outcomes among cases compared with controls, adjusted for age, sex, and population
admixture.
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whole; the differences in P-values and ORs when using these
as control subsets, compared with using combined controls,
may be due to the differences in sample size.
Results of analyses testing APOL1 genotype effects on
renal disease progression, accounting for BP medication and
goal BP, are reported in Table 6. This analysis demonstrated
that APOL1 risk (recessive) predicted the rate of progression
of renal disease; the nonsignificant heterogeneity P-value
reveals that the association between APOL1 groups and
progression did not differ significantly across medication
class and BP treatment arm.
Analysis of the achieved BP at 1 year post randomization
in these 675 AASK participants did not reveal significantly
different systolic BP, diastolic BP, or mean BP in cases
randomized to either low or usual BP treatment arm based
on the presence of two vs. less than two APOL1 risk variants.
In the case of diastolic BP, the usual treatment arm had a
trend toward a lower mean±s.d. diastolic BP in the APOL1
two risk–variant group (84.2±1.29mmHg) vs. the APOL1
less than two risk–variant group (86.2±0.76mmHg;
P¼ 0.0565). Heterogeneity P-values comparing usual and
low BP treatment arms on the basis of APOL1 risk and
nonrisk were nonsignificant, revealing that the effect of the
APOL1 risk variants on BP did not differ by treatment arm
(heterogeneity P¼ 0.6240 systolic BP; P¼ 0.3721 diastolic
BP; P¼ 0.4447 mean BP).
To test whether the AASK Trial inference changed after
adjusting for the strong effect of the APOL1 risk variants,
we computed a general linear model with age, gender, and
APOL1 G1/G2 risk variants under a recessive model as
covariates. We tested the effects of the BP arm adjusting for
the medication class and the above covariates. We also tested
for the effects of the medication class, adjusting for the BP
arm and the above covariates. Specifically, there was no effect
of the BP arm adjusting for age, gender, and APOL1 G1/G2
risk variants under a recessive model and medication class
group (P¼ 0.19). There was no effect of the medication class
group, adjusting for age, gender, and APOL1 G1/G2 risk
variants under a recessive model and the BP arm (P¼ 0.13).
Finally, there was no effect of the combined medication
treatment group and the BP arm, adjusting for age, gender,
and APOL1 G1/G2 risk variants under a recessive model
(P¼ 0.23). There was no evidence that the magnitude of the
effect of the APOL1 variants differed as a function of the BP
arm (P¼ 0.56) or medication class (P¼ 0.18).
DISCUSSION
The results presented here demonstrate that nephropathy risk
variants in the APOL1 gene, and to a lesser extent MYH9, are
significantly associated with CKD attributed to essential
hypertension in nondiabetic AASK participants compared
with controls. Evidence of genetic association was most
robust in individuals with progressive renal functional
decline and higher baseline levels of proteinuria. It is unlikely
that these variants are associated with essential hypertension
per se, as the results were consistent when comparing
hypertensive AASK cases with controls with or without high
BP. These results strongly suggest that progressive kidney
disease attributed to hypertensive nephrosclerosis in AASK
participants, particularly in those with higher baseline levels
of proteinuria, lie in the spectrum of FSGS-related kidney
disease, as in idiopathic FSGS, as well as human immuno-
deficiency virus–related, C1q-related, and idiopathic
collapsing forms of FSGS. Focal global glomerulosclerosis,
arteriolar nephrosclerosis, and interstitial scarring are
commonly present in the renal biopsies of AASK partici-
pants12 and appear to reside in this disease spectrum based
on APOL1 association.
Subjects in the AASK trial were randomized to angio-
tensin-converting enzyme (ACE) inhibitor, dihydropyridine
calcium channel blocker, or b-blockade with low and usual
BP targets (e.g., a 3 2 factorial design). Subsequently, all
participants in the continuation study, the AASK Cohort
Study, received ACE inhibitors with a low BP goal. Despite
this aggressive therapy, 54% of AASK patients experienced
the primary outcome (doubling of creatinine, ESKD, or death).13
These analyses demonstrate that APOL1 risk (recessive model)
predicted the least-squares projected slope of iothalamate
GFR during the AASK Trial phase. The nonsignificant
heterogeneity P-value reveals that medication class and BP
treatment arm did not significantly differ in effect on
progression of kidney disease across groups, accounting for
APOL1-associated genetic risk. This is consistent with the
AASK Trial results, demonstrating that a lower BP goal did
Table 6 | Effects of APOL1, blood pressure target, and medication class on rate of decline of GFR in the AASK Trial
Slope of iothalamate GFR
Medication class BP arm APOL1 non-risk APOL1 risk P-value Heterogeneity P-value
ACE inhibitor Low 1.47±0.22 2.68±0.40 0.0202
Usual 1.50±0.23 2.84±0.41 0.0023
b-Blocker Low 1.59±0.24 2.22±0.41 0.3776
Usual 2.01±0.24 2.70±0.40 0.1736
Calcium channel blocker Low 2.05±0.34 2.72±0.60 0.2542
Usual 2.18±0.33 3.17±0.62 0.2050
Meta-analysis 4.29E-05 0.6257
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; ACE, angiotensin-converting enzyme; APOL1 non-risk, less than two (G1+G2) risk variants;
APOL1 risk, two (G1+G2) risk variants; BP, blood pressure; GFR, glomerular filtration rate.
Based on least-squares projected slope of iothalamate GFR in AASK Trial phase, beginning 6 months after enrollment, APOL1 genotypes were significantly associated with rate
of kidney function decline, in contrast to no effect of blood pressure treatment goal or medication class. The meta-analysis compares APOL1 risk and non-risk genotypes
combining all six treatment cells.
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not affect renal disease progression. However, ACE inhibitors
did slow the progression of renal disease in AASK relative to
b-blockers and calcium channel blockers; the inability to
detect this in the current study may be because of the smaller
sample size. These results suggest that the failure of intensive
treatment of BP to halt the progression of renal disease is
associated with the role of APOL1 gene variants. New clinical
targets are urgently required to combat this severe genetic
form of kidney disease.
It is unclear why ACE inhibition, which often benefits
patients with heavy proteinuria, had less of a protective effect
in AASK. In this subset of AASK participants, ACE inhibition
(regardless of usual or low BP treatment arm) did not signifi-
cantly impact renal disease progression after accounting for
APOL1. Not all AASK Trial or AASK Cohort participants
were included in these genetic analyses, and hence low
power may contribute. In addition, AASK excluded parti-
cipants with 42.5 g of proteinuria per day at baseline;
most participants had a far lower level of proteinuria. Therefore,
the protective effect of ACE inhibition might have been reduced
owing to the generally lower levels of proteinuria.
Important clinical and histological differences exist
between African Americans and European Americans in
the kidney disease that is labeled hypertensive nephro-
sclerosis. African Americans develop ESKD attributed to
high BP earlier in life than European Americans.2 In
addition, successful treatment of hypertension more effec-
tively slows nephropathy progression in European Amer-
icans, relative to African Americans.14,15 Despite being
labeled with the same clinical diagnosis (hypertensive
nephrosclerosis), African Americans exhibit greater degrees
of solidified glomerulosclerosis and arteriolonephrosclero-
sis, whereas European Americans have greater degrees of
obsolescent, collapsed glomeruli.12,16 These racial differ-
ences have long hinted at different causative factors for renal
disease progression. APOL1 nephropathy risk variants are
present at high frequency in African-derived populations
and are virtually absent in European-derived and Asian
populations. Therefore, the clinical differences in nondia-
betic renal disease may primarily relate to variation in
APOL1, as it has been associated with shorter survivals of
African American–donated kidneys in the setting of
deceased donor transplantation.17 Importantly, kidneys
from African American donors without APOL1 risk variants
demonstrated excellent allograft survival, similar to Eur-
opean American–donated kidneys. Thus, APOL1 genotypes,
not race, convey risk for nephropathy.
Aggressive treatment of high BP in AASK failed to
significantly slow nephropathy progression in nondiabetic
African Americans with hypertension and CKD, particularly
among those who lacked proteinuria at baseline;11 the use of
ACE inhibitors slowed progression compared with b-blocker
or calcium channel blocker,18 but long-term progression rates
on ACE inhibitors remain high.13 Genetic influences that
may not be sensitive to ACE inhibitors or BP control have
previously been shown to contribute to this propensity for
progressive loss of kidney function among AASK partici-
pants, including variants in the adrenergic pathway19 and the
homocysteine pathway.20 We now show that in this region of
chr 22 genetic variation in APOL1, and to a lesser extent
MYH9, is strongly associated with progression of kidney
disease and may offer a new perspective on hypertension-
attributed renal disease. MYH9 has effects independent of
APOL1 on nephropathy risk in those with sickle cell disease21
and in individuals of European ancestry.8,9 There are now
abundant data that current therapies have limited ability to
slow progression of kidney disease. It is therefore critical to
understand the function of APOL1 in order to develop
improved therapeutic options to slow progression of non-
diabetic kidney disease.
MATERIALS AND METHODS
Subjects
The AASK clinical trial compared the effects of three different drugs
and two BP targets on progression of hypertension-attributed
nephropathy in 1094 African Americans recruited at 21 clinical sites
in the United States. Study subjects were self-identified African
Americans between the age of 18 and 70 years, who had a diastolic
BP 495mmHg and a measured iothalamate GFR between 20 and
65ml/min per 1.73m2. Selected exclusion criteria included evidence of
a clinical cause other than hypertension for kidney disease, diabetes
mellitus or fasting blood glucose level 4140mg/dl, urine protein/
creatinine ratio (PCR) 42.5 g/g, secondary hypertension, or acceler-
ated or malignant hypertension in the preceding 6 months.
Control subjects were recruited at the Wake Forest School of
Medicine and consisted of 948 African American subjects with
serum creatinine concentrations o1.5mg/dl in men or o1.3mg/dl
in women, of whom 410 were questioned about the presence of
hypertension and 171 (41.7%) reported having high BP.
Ethics approvals
The AASK clinical protocol was approved by the Institutional
Review Board (IRB) of each participating institution, and each
patient provided informed consent. After the trial was underway,
subjects were approached to contribute DNA as part of an Ancillary
Study that was approved by the IRB at each participating study site;
850 subjects consented and contributed blood for DNA extraction.
Control participants provided DNA and clinical information
through a protocol approved by the Wake Forest School of Medicine
IRB. All controls provided written informed consent.
Genetic analysis
DNA was genotyped for 10 SNPs on chr 22 using TaqMan assays
(Applied Biosystems, Foster City, CA), including the four MYH9 E1
haplotype SNPs (rs4821480, rs2032487, rs4821481, rs3752462) and
two other SNPs in the MYH9 region (rs5750250 and rs11912763),
the APOL1 G1 nonsynonymous SNPs (rs73885319, rs60910145), the
APOL1 G2 6-bp insertion/deletion (rs71785313), and the non-
synonymous SNP rs16996616 in the APOL1 gene. An additional 44
ancestry informative marker SNPs were genotyped in cases and
controls. The ancestry informative markers included chr 1:
rs1334336; rs2365669; rs9725312; chr 2: rs11890727; rs1868929;
chr 3: rs7627605; chr 4: rs2725267; rs12503758; rs2545258; chr 5:
rs7727623; rs6881896; rs7712675; chr 6: rs4946888; rs9388989;
rs686406; chr 7: rs3823831; rs10488004; rs520556; chr 8: rs4732942;
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rs13439780; chr 9: rs449090; rs7873820; chr 10: rs1733742; rs570677;
chr 11: rs647756; rs7952397; chr 12: rs7963493; rs4767461; chr 13:
1572018; rs11148886; chr 14: rs1956424; rs12897140; chr 15:
rs4451923; chr 16: rs10775349; rs7198976; chr 17: rs8074370; chr
19: rs901792; rs2231738; chr 20: rs1418032; rs6046024; rs1028546; chr
21: rs220245; chr 22: rs12159761; and chr 23: rs6520141. Admixture
analysis was performed with ADMIXMAP (http://homepages.ed.
ac.uk/pmckeigu/admixmap/index.html), using allele frequencies
from CEU (Utah Residents with Northern and Western European
Ancestry) and Yoruban (YRI) HapMap samples. Genotype data
for CEU and YRI were included in the analysis as anchoring
populations. Samples with YRI proportion o0.4 (three cases) were
excluded from the analysis. After quality control for missing
phenotypic data, duplicates, genotyping failures, and admixture
outliers, 675 cases and 618 controls were available for this study.
Results for SNP rs4821480 were not included in the analysis because
of technical difficulties with the TaqMan assay; its proxy, rs4821481,
was retained in the analysis. All reported SNPs conformed to
Hardy–Weinberg expectations for genotype frequencies. Slightly
different cell counts relate to covariate availability across analyses.
Analyses were performed to examine the combined risk of APOL
G1–G2 alleles and the MYH9 E1 haplotype for different clinical
phenotypes. These analyses were performed in subgroups of AASK
cases who had or developed severe CKD during the study, defined as
follows: (1) developing ESKD or serum creatinine 42mg/ml; or
(2) developing ESKD or serum creatinine 43mg/dl. Stratification
by proteinuria was evaluated as in prior AASK analyses, which
demonstrated that patients with urine PCRX0.22 g/g have a greater
risk of progression to ESKD than those with less proteinuria.11
Sensitivity analyses were performed comparing cases with controls
who had reported hypertension or normal BP.
Analyses testing APOL1 genotype effects on renal disease
progression, accounting for BP medication and goal BP, were
performed on AASK participants. Renal disease progression was
based on the least-squares projected slope of iothalamate GFR
during the AASK Trial phase (beginning at 6 months to avoid acute
medication effects). A test for whether the association varied by BP
target and/or medication class (heterogeneity P-value), as well as the
six individual tests of the association within the BP target-medication
class combinations, was performed.
Quality control
The accuracy of the E1 MYH9 and APOL1 TaqMan assays was
validated by resequencing a group of DNAs from 60 African
American donors and by genotyping several hundred African and
European controls, all of which conformed to HWE expectations
and had allele frequencies similar to those reported in dbSNP
(http://www.ncbi.nlm.nih.gov/snp). In this study, we included 10%
duplicate samples within and between plates to control for
genotyping errors; there was 100% concordance for all SNPs. All
but one SNP, rs4824180, were in HWE and showed expected patterns
of linkage disequilibrium. We therefore elected to regenotype all
MYH9 E1 SNPs and the APOL1 SNPs to confirm genotype
assignment; there was a 100% match for all SNP genotypes. SNP
rs4824180 was removed from the analysis both because it was out of
HWE (P¼ 0.0001) and because the SNP showed an implausible
pattern of linkage disequilibrium with neighboring SNPs.
Data analysis
Single SNP analysis was performed using logistic regression via
SNPGWA (http://www.phs.wfubmc.edu/public/bios/gene/downloads.
cfm), adjusting for age, gender, and admixture. The primary analysis
compared all the cases with all the controls. Subgroup analyses were per-
formed stratifying the cases by degree of renal failure: serum creatinine
(42mg/dl or ESKD vs. controls or serum creatinine 43mg/dl or
ESKD vs. controls) and degree of proteinuria (urine PCRX0.22 g/g
vs. controls and urine PCR o0.22 g/g vs. controls). As not all the
controls were phenotyped for self-reported hypertension, sensitivity
analyses were performed comparing cases with controls with docu-
mented hypertension or with documented normotension.
To determine whether both MYH9 and APOL1 risk alleles were
associated with CKD, we performed additional single SNP analyses
adjusting for APOL1 G1–G2 combined allele risk (defined as being
homozygous for the G1 allele (rs73885319 allele G) or homozygous
for the G2 allele (rs71785313 deletion), or heterozygous for both G1
and G2 alleles (one copy of the risk ‘allele’ for each marker), to assess
for residual risk of the MYH9 SNPs.
The role of the MYH9 risk haplotype (recessive model for E1 risk
haplotype, consisting of SNPs rs2032487, rs4821481, rs3752462) was
analyzed using logistic regression controlling for age, gender,
admixture, and G1–G2 alleles combined risk.
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